STCube, Inc.
Financials
Valuation Metrics
STCube, Inc.'s Market Cap is ₩6288B. At end of 2025 it was ₩5575B. Ranked #413 of 2,433 in KR market (top 17%), #141 of 1,647 on KOSDAQ (top 9%), #30 of 246 in Technology Hardware & Equipment (top 12%) by Market Cap.
Investment Metrics(as of 2026-08-14)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 628.85B KRW | KR#413/2,433 Sec#30/246 |
| Revenue | 6.54B KRW | KR#2,324/2,433 Sec#243/246 |
| Net Income | -23.98B KRW | KR—/2,433 Sec—/246 |
| Total Assets | 90.23B KRW | KR#1,844/2,433 Sec#184/246 |
| Net Assets | 72.12B KRW | KR#1,649/2,433 Sec#157/246 |
| Employees | 16 | KR#2,241/2,433 Sec#235/246 |
| Value | ||
| P/B | 8.72x | KR#2,336/2,433 Sec#236/246 |
| P/S | 96.17x | KR#2,393/2,433 Sec#245/246 |
| FCF Yield | -3.29% | KR—/2,433 Sec—/246 |
| Profitability | ||
| ROE | -33.25% | KR#2,201/2,433 Sec#224/246 |
| ROA | -26.57% | KR#2,282/2,433 Sec#237/246 |
| Op. Margin | -391.71% | KR#2,362/2,433 Sec#246/246 |
| Revenue Growth | -24.63% | KR#2,128/2,433 Sec#209/246 |
| Financial Health | ||
| Debt Ratio | 25.11% | KR#484/2,433 Sec#53/246 |
| Total Debt | 0 KRW | KR—/2,433 Sec—/246 |
| FCF | -20.68B KRW | KR#1,902/2,433 Sec#192/246 |
| Cash | 16.93B KRW | KR#1,335/2,433 Sec#133/246 |
| Current Ratio | 18.71x | KR#29/2,433 Sec#1/246 |
| Performance | ||
| 1Y Return | 23.33% | KR#457/2,433 Sec#71/246 |
| 1M Return | 18.59% | KR#324/2,433 Sec#36/246 |
| From 52W High | -58.89% | KR#1,848/2,433 Sec#174/246 |
| 1Y MDD | -70.63% | KR#1,980/2,433 Sec#190/246 |
| Trading | ||
| Volume | 149,801 shares | KR#757/2,433 Sec#87/246 |
| Trading Value | 1.37B KRW | KR#734/2,433 Sec#76/246 |
| Foreign Own. | 6.39% | KR#661/2,433 Sec#70/246 |
| Per Share | ||
| EPS | -353 KRW | KR—/2,433 Sec—/246 |
| BPS | 1,061 KRW | KR#2,275/2,433 Sec#223/246 |
Company Info
STCube, established in 1989 and listed on KOSDAQ in 2001, is a diversified company engaged in bio, cosmetics, and IT distribution. In collaboration with STCube Pharmaceuticals, Inc., it develops anti-cancer immunotherapies and conducts cosmetics manufacturing, sales, and distribution under its brand, C-NALS. The company is actively conducting global clinical trials for its innovative new drug, Nelmastobart, and engaging with multinational pharmaceutical companies to strengthen global competitiveness and diversify its drug pipeline. It is headquartered in Gangnam-gu, Seoul.